Impact Factor 4.137 | CiteScore 4.28
More on impact ›

Correction ARTICLE

Front. Oncol., 27 September 2019 | https://doi.org/10.3389/fonc.2019.00990

Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway

Hanbo Cao1, Wenjun Li1, Yizhou Zhou1, Renxiang Tan2, Yue Yang1, You Zhou1, Qinglong Guo1* and Li Zhao1*
  • 1State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, China
  • 2State Key Laboratory Cultivation Base for TCM Quality and Efficacy, Nanjing University of Chinese Medicine, Nanjing, China

A Corrigendum on
Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway

by Cao, H., Li, W., Zhou, Y., Tan, R., Yang, Y., Zhou, Y., et al. (2019). Front. Oncol. 9:188. doi: 10.3389/fonc.2019.00188

In the original article, there was a mistake in Figure 3H as published. Due to carelessness, the picture of the “k562-indo group” was accidentally placed in the “ku812-indo group”. The corrected Figure 3H appears below.

FIGURE 3
www.frontiersin.org

Figure 3.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: bone marrow environment, CXCL12/CXCR4, oroxylin A, Imatinib (IM), β-catenin/P-gp

Citation: Cao H, Li W, Zhou Y, Tan R, Yang Y, Zhou Y, Guo Q and Zhao L (2019) Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway. Front. Oncol. 9:990. doi: 10.3389/fonc.2019.00990

Received: 09 September 2019; Accepted: 16 September 2019;
Published: 27 September 2019.

Edited and reviewed by: Carmen Alvarez-Lorenzo, University of Santiago de Compostela, Spain

Copyright © 2019 Cao, Li, Zhou, Tan, Yang, Zhou, Guo and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Qinglong Guo, anticancer_drug@163.com; Li Zhao, zhaoli@cpu.edu.cn